• 1
    Miller E, Hoschler K, Hardelid P et al. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010; 375:11001108.
  • 2
    Veguilla V, Hancock K, Schiffer J et al. Sensitivity and specificity of serologic assays for the detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Microbiol 2011; 49:22102215.
  • 3
    Chen MI, Barr IG, Koh GCH et al. Serological response in RT-PCR confirmed H1N1-2009 influenza A by hemagglutination inhibition and virus neutralization assays: an observational study. PLoS One 2010; 5:e12474.
  • 4
    Iwasenko JM, Cretikos M, Paterson DL et al. Enhanced diagnosis of pandemic (H1N1) 2009 influenza infection using molecular and serological testing in intensive care unit patients with suspected influenza. Clin Infect Dis 2010; 51:7072.
  • 5
    Papenburg J, Baz M, Hamelin ME et al. Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratory-confirmed secondary attack rates and evidence of asymptomatic infections. Clin Infect Dis 2010; 51:10331041.
  • 6
    Fineberg HV, et al. WHO Report of the Review Committee on the Functioning of the International Health Regulations (2005) and on Pandemic Influenza A (H1N1) 2009. Available from (Accessed 11 April 2012).
  • 7
    Nicoll A, Gill ON, Peckham CS et al. The public health applications of unlinked anonymous seroprevalence monitoring for HIV in the United Kingdom. Int J Epidemiol 2000; 29:110.
  • 8
    Van Kerkhove MD, Asikainen T, Becker NG et al. Studies needed to address public health challenges of the 2009 H1N1 influenza pandemic: insights from modeling. PLos Med 2010; 7:e1000275.
  • 9
    National Institute of Infectious Diseases T, Japan. National Serum Reference Bank, National Epidemiological Surveillance of Vaccine-Preventable Diseases. [cited]. Available from (Accessed 12 April 2012).
  • 10
    Osborne K, Gay N, Hesketh L, Morgan-Capner P, Miller E. Ten years of serological surveillance in England and Wales: methods, results, implications and action. Int J Epidemiol 2000; 29:362368.
  • 11
    van der Klis FR, Mollema L, Berbers GA, de Melker HE, Coutinho RA. Second national serum bank for population-based seroprevalence studies in the Netherlands. Neth J Med 2009; 67:301308.
  • 12
    Hancock K, Veguilla V, Lu X et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 20:19451952.
  • 13
    Katz JM, Hancock K, Veguilla V et al. Serum cross-reactive antibody response to a novel influenza A(H1N1) virus after vaccination with seasonal influenza vaccine. MMWR 2009; 58:521524.
  • 14
    Itoh Y, Shinya K, Kiso M et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009; 7258:10211025.
  • 15
    Fry AM, Hancock K, Patel M et al . The first cases of 2009 pandemic influenza A (H1N1) virus infection in the United States: a serologic investigation demonstrating early transmission. Influenza Other Respi Viruses 2012; 6:e4853.
  • 16
    Jackson ML, France AM, Hancock K et al. Serologically confirmed household transmission of 2009 pandemic influenza A(H1N1) virus during the first pandemic wave — New York City, April–May 2009. Clin Infect Dis 2011; 53:455462.
  • 17
    Johnson S, Ihekweazu C, Hardelid P et al. A seroepidemiology study of novel pandemic influenza (H1N1) 2009 during an outbreak in a boarding school. Emerg Infect Dis 2011; 17:16701677.
  • 18
    Fraser C, Donnelly CA, Cauchemez S et al. Pandemic potential of a strain of influenza A(H1N1): early findings. Science 2009; 324:15571561.
  • 19
    Lessler J, Reich NG, Cummings DAT, NYC Department of Health and Mental Hygiene Swine Influenza Investigation Team. Outbreak of 2009 pandemic influenza A(H1N1) at a New York City school. N Engl J Med 2009; 361:26282836.
  • 20
    McBryde ES, Bergeri I, van Gemert C et al. Early transmission characteristics of influenza A(H1N1)v in Australia: Victorian state, 16 May-3 June 2009. Eurosurveillance 2009; 14:19363.
  • 21
    Smith A, Coles S, Johnson S, Saldana L, Ihekweazu C, O’Moore É. An outbreak of influenza A(H1N1)V in a boarding school in south east England, May-June 2009. Eurosurveillance 2009; 14:pii=19263.
  • 22
    Maines TR, Jayaraman A, Belser JA et al. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 2009; 325:484487.
  • 23
    Munster VJ, de Wit E, van den Brand JM et al. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 2009; 325:481483.
  • 24
    ANZIC II. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009; 361:19251934.
  • 25
    Jamieson DJ, Honein MA, Rasmussen SA et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 2009; 374:451458.
  • 26
    Nguyen-Van-Tam JS, Openshaw PJ, Hashim A et al. Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). Thorax 2010; 65:645651.
  • 27
    Van Kerkhove MD, Vandemaele K, Shinde V et al. on behalf of the WHO Working Group on Risk Factors for Severe H1N1pdm Infection. Risk factors for severe outcomes following 2009 Influenza A (H1N1) infection: a global pooled analysis. PLos Med 2011; 8:e1001053.
  • 28
    Bandaranayake D, Huang QS, Bissielo A et al. Risk factors and immunity in a nationally representative population following the 2009 influenza A(H1N1) pandemic. PLoS One 2010; 5:e13211.
  • 29
    Chen MIC, Lee VJM, Lim WY et al. 2009 Influenza A(H1N1) seroconversion rates and risk factors among distinct adult cohorts in Singapore. JAMA 2010; 303:13831391.
  • 30
    Dowse GK, Smith DW, Kelly H et al. Incidence of pandemic (H1N1) 2009 influenza infection in children and pregnant women during the 2009 influenza season in Western Australia — a seroprevalence study. Med J Aust 2011; 194:6872.
  • 31
    Gilbert GL, Cretikos MA, Hueston L, Doukas G, O’Toole B, Dwyer DE. Influenza A(H1N1) 2009 antibodies in residents of New South Wales, Australia, after the first pandemic wave in the 2009 Southern Hemisphere winter. PLoS One 2010; 5:e12562.
  • 32
    McVernon J, Laurie KL, Nolan T et al. Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October–December 2009. Eurosurveillance 2010; 15:19678.
  • 33
    Tandale BV, Pawar SD, Gurav YK et al. Seroepidemiology of pandemic influenza A(H1N1) 2009 virus infections in Pune, India. BMC Infect Dis 2010; 10:255.
  • 34
    Waalen K, Kilander A, Dudman SG, Krogh GH, Aune T, Hungnes O. High prevalence of antibodies to the 2009 pandemic influenza A(H1N1) virus in the Norwegian population following a major epidemic and a large vaccination campaign in autumn 2009. Eurosurveillance 2010; 15:19633.
  • 35
    Wu JT, Ma ESK, Lee CK et al. The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. Clin Infect Dis 2010; 51:11841191.
  • 36
    Xu C, Bai T, Iuliano AD et al. The seroprevalence of pandemic influenza H1N1 (2009) virus in China. PLoS One 2011; 6:e17919.
  • 37
    Riley S, Kwok KO, Wu KM et al. Epidemiological characteristics of 2009 pandemic influenza based on paired sera from a prospective community cohort. PLos Med 2011; 8:e1000442.
  • 38
    Jaeger J, Patel M, Dharan N et al. Transmission of 2009 pandemic influenza A(H1N1) virus among healthcare personnel-Southern California, 2009. Infect Control Hosp Epidemiol 2011; 32:11491157.
  • 39
    Chen MI, Lee VJ, Barr I et al. Risk factors for pandemic (H1N1) 2009 virus seroconversion among hospital staff, Singapore. Emerg Infect Dis 2010; 16:15541561.
  • 40
    Trauer JM, Laurie K, McDonnell J, Kelso A, Markey PG. Differential impact of pandemic (H1N1) 2009 on remote and Indigenous groups in the Northern Territory, Australia. Emerg Infect Dis 2011; 17:16151623.
  • 41
    Mahmud SM, Becker M, Keynan Y et al. Estimated cumulative incidence of pandemic (H1N1) influenza among pregnant women during the first wave of the 2009 pandemic. Can Med Assoc J 2010; 182:15221524.
  • 42
    Lee VJ, Yap J, Cook AR et al. Effectiveness of public health measures in mitigating pandemic influenza spread: a prospective sero-epidemiological cohort study. J Infect Dis 2010; 202:13191326.
  • 43
    Lee VJ, Yap J, Tay JK et al. Seroconversion and asymptomatic infections during oseltamivir prophylaxis against influenza A H1N1 2009. BMC Infect Dis 2010; 10:164.
  • 44
    Cowling BJ, Chan KH, Fang VJ et al. Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med 2010; 362:21752184.
  • 45
    Aho M, Lyytikainen O, Nyholm JE et al. Outbreak of 2009 pandemic influenza A(H1N1) in a Finnish garrison – a serological survey. Eurosurveillance 2011; 15:19709.
  • 46
    Wood J, Heath A. Report of a WHO Collaborative Study to Assess the Suitability of a Candidate International Standard for Antibody to Pandemic H1N1 Influenza Virus. WHO Press, World Health Organization, 2010. Contract No.: Document Number|WHO/BS/10.2137.
  • 47
    WHO. Seroepidemiologic studies for the 2009 influenza A H1N1 pandemic. Wkly Epidemiol Rec 2010; 85:229236.
  • 48
    von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLos Med 2007; 4:e296.
  • 49
    European Union Council. Decision No 2119/98/EC. L 268 ed; 1998. p. P. 0001-7. Available at (Accessed 12 April 2012).
  • 50
    Witt CJ, Richards AL, Masuoka PM et al. The AFHSC-Division of GEIS Operations Predictive Surveillance Program: a multidisciplinary approach for the early detection and response to disease outbreaks. BMC Public Health 2011; 11(Suppl 2):S10.
  • 51
    World Health Organization GISN. Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza. 2011. [updated 2011; cited]; Available from (Accessed 12 April 2012).
  • 52
    Stephenson I, Das RG, Wood JM, Katz JM. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 2007; 25:40564063.
  • 53
    Stephenson I, Heath A, Major D et al. Reproducibility of serologic assays for influenza virus A(H5N1). Emerg Infect Dis 2009; 15:12501259.
  • 54
    Wood JM, Gaines-Das RE, Taylor J, Chakraverty P. Comparison of influenza serological techniques by international collaborative study. Vaccine 1994; 12:167174.
  • 55
    Kelly H, Peck HA, Laurie KL, Wu P, Nishiura H, Cowling BJ. The age-specific cumulative incidence of infection with pandemic influenza H1N1 2009 was similar in various countries prior to vaccination. PLoS One 2011; 6:e21828.
  • 56
    Broberg E, Nicoll A, Amato-Gauci A. Seroprevalence to influenza A(H1N1) 2009 virus – where are we? Clin Vaccine Immunol 2011; 18:120512.
  • 57
    Andrews N, Tischer A, Sledler A et al. Towards elimination: measles susceptibility in Australia and 17 European countries. Bull World Health Organ 2008; 86:197204.
  • 58
    Cagney M, MacIntyre CR, McIntyre P, Puech M, Giammanco A. The seroepidemiology of pertussis in Australia during an epidemic period. Epidemiol Infect 2006; 134:12081216.
  • 59
    Chandy S, Yoshimatsu K, Ulrich RG et al. Seroepidemiological study on hantavirus infections in India. Trans R Soc Trop Med Hyg 2008; 102:7074.
  • 60
    Forshey BM, Guevara C, Laguna-Torres VA et al. Arboviral etiologies of acute febrile illnesses in Western South America, 2000-2007. PLoS Negl Trop Dis 2010; 10:e787.
  • 61
    Hardelid P, Andrews NJ, Hoschler K et al. Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A/H1N1 2009. Health Technol Assess 2010; 14:115192.
  • 62
    CDC. National Health and Nutrition Examination Survey, Serum Samples III. [cited]; Available from (Accessed 12 April 2012).
  • 63
    NHS. Facilitating and Promoting Ethical Research. 2011. [updated 2011; cited]; Available from (Accessed 12 April 2012).
  • 64
    WHO-CIOMS. International Ethical Guidelines for Biomedical Research Involving Human Subjects. 2002. [updated 2002; cited]; Available from (Accessed April 12 2012).
  • 65
    Vong S, Ly S, Van Kerkhove M et al. Risks for H5N1 infections from Poultry to Humans in Cambodia, 2006. J Infect Dis 2009; 199:19.
  • 66
    Holm S. The Danish Research Ethics Committee System, Overview and Critical Assessment (Research Involving Human Participants V2). [cited 2011 July 8]; Available from (Accessed 12 April 2012).
  • 67
    NHMRC. Harmonisation of Multi-Centre Ethical Review (HoMER). [cited]; Available from (Accessed 12 April 2012).
  • 68
    Heptonstall J, Gill ON. The legal and ethical basis for unlinked anonymous HIV Testing. CDR Weekly 1989; 89:36. Available from (Accessed 12 April 2012).
  • 69
    Hepple B, Smith P, Brownsword R et al. Public Health: Ethical Issues. London: Nuffield Council on Bioethics, 2007. Available at (Accessed 12 April 2012).
  • 70
    Gill ON, Adler MW, Day NE. Monitoring the prevalence of HIV. Br Med J 1989; 299:12951298.
  • 71
    Datta J, Kessel A, Wellings K et al. The views of genitourinary medicine (GUM) clinic users on unlinked anonymous testing for HIV: evidence from a pilot study of clinics in two English cities. J Med Ethics 2011; 37:668672.
  • 72
    Kessel A, Watts C, Weiss HA. Bad blood? Survey of public’s views on unlinked anonymous testing of blood for HIV and other diseases. Br Med J 2000; 320:e1.
  • 73
    Ochiai H, Shibata M, Kamimura K, Niwayama S. Evaluation of the efficacy of split-product trivalent A(H1N1), A(H3N2), and B influenza vaccines: reactogenicity, immunogenicity and persistence of antibodies following two doses of vaccines. Microbiol Immunol 1986; 30:11411149.
  • 74
    Song JY, Cheong HJ, Hwang IS et al. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine 2010; 28:39293935.
  • 75
    Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70:767777.
  • 76
    Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979; 35:6975.
  • 77
    Fox JP, Cooney MK, Hall CE, Foy HM. Influenzavirus infections in Seattle families, 1975–1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am J Epidemiol 1982; 116:228242.
  • 78
    Ekiert DC, Bhabha G, Elsliger MA et al. Antibody recognition of a highly conserved influenza virus epitope: implications for universal prevention and therapy. Science 2009; 324:246251.
  • 79
    Sui J, Hwang W, Perez S et al. Structural and functional bases from broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16:265273.
  • 80
    Greenbaum JA, Kotturi MF, Kim Y et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A 2009; 106:2036520370.
  • 81
    Nicoll A, Ammon A, Amato Gauci A et al. Experience and lessons from surveillance and studies of the 2009 pandemic in Europe. Public Health 2010; 124:1423.
  • 82
    Katz JM, Hancock K, Xu X. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expt Rev Anti Infect Ther 2011; 9:669683.
  • 83
    Zambon M. Laboratory diagnosis of influenza; in Nicholson KG, Webster RG, Hay AJ (eds): Textbook of Influenza. Oxford: Blackwell Science, 1998; pp. 291313.
  • 84
    Chang SC, Chang CM, Huang YC, Chiu CH, Shih SR, Lin TY. Preexisitng antibodies against pandemic 2009 influenza A(H1N1) virus in Taiwan. Clin Infect Dis 2010; 51:14651467.
  • 85
    Chen H, Wang Y, Liu W, Zhang J, Dong B, Fan X. Serological survey of pandemic (H1N1) 2009 virus, Guanxi Province, China. Emerg Infect Dis 2009; 15:18491850.
  • 86
    Tang JW, Tambyah PA, Wilder-Sminth A, Puong K-Y, Shaw R, Barr IG. Cross-reactive antibodies to influenza (H1N1) 2009 virus, Singapore. Emerg Infect Dis 2010; 16:874876.
  • 87
    Ikonen N, Strengell M, Kinnunen L et al. High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland. Eurosurveillance 2010; 15:19478.
  • 88
    Rizzo C, Rota MC, Bella A et al. Cross-reactive antibody responses to the 2009 A/H1N1v influenza virus in the Italian population in the pre-pandemic period. Vaccine 2010; 28:35583562.
  • 89
    Zhu FC, Wang H, Fang HH et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 25:24142423.
  • 90
    Jiang T, Li X, Liu W et al. Serum antibody response to the novel influenza A(H1N1) virus in the elderly. Clin Infect Dis 2010; 50:285286.
  • 91
    Chi CY, Liu CC, Lin CC et al. Preexisiting antibody response against 2009 pandemic influenza H1N1 viruses in the Taiwanese population. Clin Vaccine Immunol 2010; 17:19581962.
  • 92
    Chan YJ, Lee CL, Hwang SJ et al. Seroprevalence of antibodies to pandemic (H1N1) 2009 influenza virus among hospital staff in a medical center in Taiwan. J Chin Med Assoc 2010; 73:6266.